Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT01806064
Title A Phase 1B Dose-escalation Study of TRC105 in Combination With Axitinib in Patients With Advanced Renal Cell Carcinoma
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Tracon Pharmaceuticals Inc.

renal cell carcinoma


Bevacizumab + Carotuximab

Age Groups: adult
Covered Countries USA

No variant requirements are available.